182 related articles for article (PubMed ID: 27756161)
41. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
42. Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.
Hayden RE; Pratt G; Drayson MT; Bunce CM
Haematologica; 2010 Nov; 95(11):1889-96. PubMed ID: 20634492
[TBL] [Abstract][Full Text] [Related]
43. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand.
Buske C; Gogowski G; Schreiber K; Rave-Fränk M; Hiddemann W; Wörmann B
Exp Hematol; 1997 Apr; 25(4):329-37. PubMed ID: 9131008
[TBL] [Abstract][Full Text] [Related]
44. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Pavlasova G; Borsky M; Svobodova V; Oppelt J; Cerna K; Novotna J; Seda V; Fojtova M; Fajkus J; Brychtova Y; Doubek M; Pospisilova S; Mayer J; Mraz M
Leukemia; 2018 Sep; 32(9):2028-2031. PubMed ID: 30030508
[No Abstract] [Full Text] [Related]
45. Microenvironmental interactions and survival of CLL B-cells.
Munk Pedersen I; Reed J
Leuk Lymphoma; 2004 Dec; 45(12):2365-72. PubMed ID: 15621749
[TBL] [Abstract][Full Text] [Related]
46. Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype.
Best OG; Mulligan SP
Leuk Lymphoma; 2012 Nov; 53(11):2314-20. PubMed ID: 22646928
[TBL] [Abstract][Full Text] [Related]
47. Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche?
Vaisitti T; Arruga F; Deaglio S
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29649100
[TBL] [Abstract][Full Text] [Related]
48. CD84 mediates CLL-microenvironment interactions.
Marom A; Barak AF; Kramer MP; Lewinsky H; Binsky-Ehrenreich I; Cohen S; Tsitsou-Kampeli A; Kalchenko V; Kuznetsov Y; Mirkin V; Dezorella N; Shapiro M; Schwartzberg PL; Cohen Y; Shvidel L; Haran M; Becker-Herman S; Herishanu Y; Shachar I
Oncogene; 2017 Feb; 36(5):628-638. PubMed ID: 27452524
[TBL] [Abstract][Full Text] [Related]
49. Expression and function of the TL1A/DR3 axis in chronic lymphocytic leukemia.
Cavallini C; Lovato O; Bertolaso A; Zoratti E; Malpeli G; Mimiola E; Tinelli M; Aprili F; Tecchio C; Perbellini O; Scarpa A; Zamò A; Cassatella MA; Pizzolo G; Scupoli MT
Oncotarget; 2015 Oct; 6(31):32061-74. PubMed ID: 26393680
[TBL] [Abstract][Full Text] [Related]
50. Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia.
von Heydebrand F; Fuchs M; Kunz M; Voelkl S; Kremer AN; Oostendorp RAJ; Wilke J; Leitges M; Egle A; Mackensen A; Lutzny-Geier G
Stem Cells; 2021 Jun; 39(6):819-830. PubMed ID: 33539629
[TBL] [Abstract][Full Text] [Related]
51. CD62L as a therapeutic target in chronic lymphocytic leukemia.
Burgess M; Gill D; Singhania R; Cheung C; Chambers L; Renyolds BA; Smith L; Mollee P; Saunders N; McMillan NA
Clin Cancer Res; 2013 Oct; 19(20):5675-85. PubMed ID: 23948971
[TBL] [Abstract][Full Text] [Related]
52. Thioredoxin, produced by stromal cells retrieved from the lymph node microenvironment, rescues chronic lymphocytic leukemia cells from apoptosis in vitro.
Bäckman E; Bergh AC; Lagerdahl I; Rydberg B; Sundström C; Tobin G; Rosenquist R; Linderholm M; Rosén A
Haematologica; 2007 Nov; 92(11):1495-504. PubMed ID: 18024398
[TBL] [Abstract][Full Text] [Related]
53. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features.
Bojarska-Junak A; Hus I; Chocholska S; Wasik-Szczepanek E; Sieklucka M; Dmoszyńska A; Roliński J
Leuk Res; 2009 Oct; 33(10):1319-27. PubMed ID: 19395025
[TBL] [Abstract][Full Text] [Related]
54. Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.
Hartmann TN; Pleyer L; Desch P; Egle A; Greil R
Discov Med; 2009 Oct; 8(42):157-64. PubMed ID: 19833065
[TBL] [Abstract][Full Text] [Related]
55. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
Zhang W; Trachootham D; Liu J; Chen G; Pelicano H; Garcia-Prieto C; Lu W; Burger JA; Croce CM; Plunkett W; Keating MJ; Huang P
Nat Cell Biol; 2012 Feb; 14(3):276-86. PubMed ID: 22344033
[TBL] [Abstract][Full Text] [Related]
56. Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia.
Cai Y; Feng L; Wang X
Crit Rev Oncol Hematol; 2018 Jun; 126():24-31. PubMed ID: 29759563
[TBL] [Abstract][Full Text] [Related]
57. Treatment of Chronic Lymphocytic Leukemia.
Burger JA
N Engl J Med; 2020 Jul; 383(5):460-473. PubMed ID: 32726532
[No Abstract] [Full Text] [Related]
58. Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
Biagi E; Rousseau R; Yvon E; Schwartz M; Dotti G; Foster A; Havlik-Cooper D; Grilley B; Gee A; Baker K; Carrum G; Rice L; Andreeff M; Popat U; Brenner M
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6916-23. PubMed ID: 16203783
[TBL] [Abstract][Full Text] [Related]
59. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.
Jak M; Mous R; Remmerswaal EB; Spijker R; Jaspers A; Yagüe A; Eldering E; Van Lier RA; Van Oers MH
Leuk Lymphoma; 2009 May; 50(5):788-801. PubMed ID: 19452318
[TBL] [Abstract][Full Text] [Related]
60. A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).
Choquette T; Henson ES; Yang X; Johnston JB; Gibson SB
Leuk Lymphoma; 2023 Apr; 64(4):822-834. PubMed ID: 36803637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
